ATHX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 saus. 2024 @ 22:58):

Stats
Šios dienos apimtis	6.46M
Vidutinė apimtis	1.77M
Rinkos kapitalizacija	833 204
EPS	$0 ( 2024-03-29 )
Kita pelno data	( $0 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.00818
ATR14	$0.00600 (26.55%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-18	Hansen Maia	Sell	67	Common Stock
2023-10-04	Hansen Maia	Sell	23 149	Common Stock
2023-10-04	Camardo Daniel A.	Sell	19 993	Common Stock
2023-09-18	Hansen Maia	Sell	67	Common Stock
2023-08-17	Mayhugh Neema	Buy	27 428	NonQualified Stock Option (right to purchase)

INSIDER POWER
23.33
Last 94 transactions
Buy: 8 476 520 \| Sell: 1 272 175

Tūris Koreliacija

Ilgas: -0.02 (neutral)

Trumpas: 0.37 (neutral)

Signal:(49.051) Neutral

Athersys Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ADN	0.951
INVZ	0.95
ARVL	0.946
ATNF	0.946
KZR	0.944
CAAS	0.943
MPAA	0.94
BPYPN	0.939
PETS	0.939
MMAT	0.939

10 Labiausiai neigiamai susiję koreliacijos
NVCN	-0.951
STAY	-0.929
TIOA	-0.926
AVEO	-0.924
VCXA	-0.921
XM	-0.92
PCRX	-0.919
BRIVU	-0.919
ITMR	-0.915
ENER	-0.914

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Athersys Inc Koreliacija - Valiuta/Žaliavos

0.85
( strong )

0.79
( moderate )

0.00
( neutral )

0.78
( moderate )

-0.40
( neutral )

-0.67
( moderate negative )

Athersys Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$5.33M
Bruto pelnas:	$5.33M (100.00 %)
EPS:	$-5.70

FY	2022
Pajamos:	$5.33M
Bruto pelnas:	$5.33M (100.00 %)
EPS:	$-5.70

FY	2021
Pajamos:	$5 514.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$0

FY	2020
Pajamos:	$1.44M
Bruto pelnas:	$1.44M (100.00 %)
EPS:	$-0.420

Financial Reports:

No articles found.

Athersys Inc

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.